7V3 Stock Chart & Stats
€0.35
>-€0.01(-1.59%)
At close: 4:00 PM EST
€0.35
>-€0.01(-1.59%)
Day’s Range― - ―
52-Week Range€0.09 - €0.56
Previous CloseN/A
Volume0.00
Average Volume (3M)1.37K
Market Cap
€32.66M
Enterprise Value€311.57M
Total Cash (Recent Filing)€221.96M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)1.9
Beta1.25
Next Earnings
Nov 25, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.68
Shares Outstanding281,944,980
10 Day Avg. Volume4,114
30 Day Avg. Volume1,371
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.91
Price to Sales (P/S)3.28
P/FCF Ratio6.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.08Price Target Upside207.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.07
Revenue Forecast (FY)€94.85K
Bulls Say, Bears Say
Bulls Say
Cash GenerationTTM operating and free cash flow of about 164.8M and 164.7M, with FCF-to-net-income near 1.00, indicates that current reported earnings are converting into cash. That supports internally funded development and reduces reliance on external capital while this cash profile persists.
Debt-Free Balance SheetZero debt across the periods shown materially reduces mandatory financing costs and refinancing exposure. Positive TTM equity of about 263.8M and assets of 307.7M provide a stronger cushion for clinical investment and operating volatility than a leveraged balance sheet.
Recent ProfitabilityTTM revenue of about 317.3M and net and EBIT margins above 50% show a strong recent profitability inflection. If retained, this earnings base could support continued pipeline development and strengthen the company’s financial capacity over the next several quarters.
Bears Say
Unproven Earnings DurabilityRecorded results from 2021–2024 show no revenue and large losses, contrasting sharply with the latest profit. This history indicates that earnings are not yet proven through a full cycle, making the current operating base less predictable for funding the pipeline over the next several quarters.
Milestone Revenue DependenceFinancial analysis identifies a model likely dependent on milestone or one-time items. Such income can produce strong reported margins without establishing recurring product demand, so future revenue and cash generation may be uneven and less dependable for sustained research and development funding.
Cash Flow VolatilityOperating and free cash flow were deeply negative during 2021–2024, while equity was notably lower in 2024 than prior years. This demonstrated sensitivity to operating outcomes can increase reliance on external financing or constrain development if the recent earnings inflection weakens.
Cantargia AB News
7V3 FAQ
What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was €0.09 and its highest was €0.56 in the past 12 months.
What is Cantargia AB’s market cap?
Cantargia AB’s market cap is €32.66M.
When is Cantargia AB’s upcoming earnings report date?
Cantargia AB’s upcoming earnings report date is Nov 25, 2026 which is in 41 days.
How were Cantargia AB’s earnings last quarter?
Cantargia AB released its earnings results on Aug 19, 2026. The company reported -€0.012 earnings per share for the quarter, beating the consensus estimate of -€0.015 by €0.004.
Is Cantargia AB overvalued?
According to Wall Street analysts Cantargia AB’s price is currently Undervalued.
Does Cantargia AB pay dividends?
Cantargia AB does not currently pay dividends.
What is Cantargia AB’s EPS estimate?
Cantargia AB’s EPS estimate is -0.01.
How many shares outstanding does Cantargia AB have?
Cantargia AB has 281,944,980 shares outstanding.
What happened to Cantargia AB’s price movement after its last earnings report?
Cantargia AB reported an EPS of -€0.012 in its last earnings report, beating expectations of -€0.015. Following the earnings report the stock price went down -6.767%.
Which hedge fund is a major shareholder of Cantargia AB?
Currently, no hedge funds are holding shares in DE:7V3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cantargia AB
Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.
7V3 Stock 12 Month Forecast
Average Price Target
€1.08
▲(207.40% Upside)
Technical Analysis
BioInvent International AB
―
Oncopeptides AB
―
Isofol Medical AB
―
Elicera Therapeutics AB
―
Immunicum AB
―